Finance

Lists
Q3 2026 earnings • released • EPS beat +23.93% • Revenue beat +12.14%
See results
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$961.26
+3.60%
(+33.37) 1D
$967.89
+0.69% (+6.63)
After hours
Closed: Nov 2, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for REGN...
Open
$927.22
High
$974.00
Low
$927.00
Mkt. cap
98.97B
Avg. vol.
753.59K
Volume
1.66M
Dividend
0.39%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
23.77
52-wk high
$974.00
52-wk low
$591.52
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
Open
$927.22
High
$974.00
Low
$927.00
Mkt. cap
98.97B
Avg. vol.
753.59K
Volume
1.66M
Dividend
0.39%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
23.77
52-wk high
$974.00
52-wk low
$591.52
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com
Analyst ratings
Based on 24 analysts giving stock ratings to REGN in the past 3 months
Buy
Buy
16
Hold
8
Sell
0
12-month forecast
Based on 24 Wall Street analysts offering 12 month price targets for REGN in the last 3 months.
Highest
Current $961.26
$1,175.00 (+22.24%)
Average
$952.75 (-0.89%)
Lowest
$770.00 (-19.90%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Risinger
Leerink Partners
Hold
Maintained
$997.00
+3.7%
11/02/2026
Joon Lee
UBS
Buy
Maintained
$1,068.00
+11.1%
11/02/2026
William Pickering
Bernstein
Hold
Maintained
$812.00
-15.5%
11/02/2026
Gregory Renza
Truist Financial
Buy
Maintained
$982.00
+2.2%
11/02/2026
Carter Gould
Cantor Fitzgerald
Buy
Maintained
$980.00
+1.9%
11/02/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$1,100.00
+14.4%
11/02/2026
John Newman
Canaccord Genuity
Buy
Maintained
$1,175.00
+22.2%
11/02/2026
Brian Skorney
Robert W. Baird
Hold
Reiterated
$875.00
-9%
11/02/2026
Terence Flynn
Morgan Stanley
Hold
Reiterated
$855.00
-11.1%
11/02/2026
Geoff Meacham
Citi
Hold
Maintained
$825.00
-14.2%
11/02/2026
Biren Amin
Piper Sandler
Buy
Maintained
$1,000.00
+4%
10/30/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$1,050.00
+9.2%
10/30/2026
Christopher Raymond
Raymond James
Buy
Maintained
$1,020.00
+6.1%
10/30/2026
Brian Abrahams
RBC Capital
Hold
Reiterated
$913.00
-5%
10/30/2026
Mohit Bansal
Wells Fargo
Hold
Maintained
$925.00
-3.8%
10/30/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$1,030.00
+7.2%
10/30/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$980.00
+1.9%
10/21/2026
Unknown Analyst
UBS
Buy
Upgraded
$978.00
+1.7%
10/14/2026
Louise Chen
Scotiabank
Hold
Maintained
$770.00
-19.9%
10/14/2026
Evan Seigerman
BMO Capital
Buy
Maintained
$920.00
-4.3%
10/12/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$972.00
+1.1%
10/01/2026
Eliana Merle
Barclays
Buy
Maintained
$917.00
-4.6%
10/02/2026
Akash Tewari
Jefferies
Buy
Maintained
$930.00
-3.3%
10/01/2026
Jasper Hellweg
Argus Research
Buy
Upgraded
$850.00
-11.6%
09/30/2026
Eve Burstein
Bernstein
Hold
Maintained
$756.00
-21.4%
09/25/2026
Rajesh Kumar
HSBC
Buy
Maintained
$920.00
-4.3%
09/10/2026
Alexandria Hammond
Wolfe Research
Buy
Reiterated
$860.00
-10.5%
05/18/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$825.00
-14.2%
05/18/2026
Nicholas Lorusso
TD Cowen
Buy
Maintained
$960.00
-0.1%
05/06/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$865.00
-10%
04/30/2026
Last report
Oct 30, 2026
Fiscal period
Q3 2026
$20.07 / $16.19
+23.93%beat
Revenue / Est. (USD)
5.12B / 4.56B
+12.14%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
3.88B
3.61B
4.29B
5.12B
Cost of goods sold
2.21B
2.21B
2.21B
2.37B
Cost of revenue
2.21B
2.21B
2.21B
2.37B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
775.00M
647.70M
662.10M
677.80M
Operating expense
775.00M
647.70M
662.10M
677.80M
Total operating expenses
2.99B
2.86B
2.87B
3.05B
Operating income
898.60M
744.80M
1.42B
2.07B
Other non operating income
958.50M
-7.30M
100.00K
4.40M
EBT including unusual items
1.04B
831.20M
1.53B
2.28B
EBT excluding unusual items
2.04B
908.10M
1.59B
2.25B
Income tax expense
199.10M
104.00M
230.90M
335.40M
Effective tax rate
19.08%
12.51%
15.11%
14.68%
Other operating expenses
-
-
-
-
Net income
844.60M
727.20M
1.30B
1.95B
Net profit margin
21.74%
20.17%
30.23%
38.09%
Earnings per share
11.44
9.47
14.29
20.07
Interest and investment income
193.30M
183.50M
183.30M
181.80M
Interest expense
-12.20M
-12.90M
-11.00M
-10.60M
Net interest expenses
181.10M
170.60M
172.30M
171.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.04B
868.00M
1.54B
2.19B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps